PGR and neoplasm: In the tumor dataset (case, n = 90), there were 81.11% estrogen receptor-positive (ER+ve), 75.56% progesterone receptor-positive (PR+ve), 78.89% human epidermal growth factor receptor 2 (HER2)-negative (HER2−ve), and only 8.89% triple-negative (ER−ve, PR−ve, and HER2−ve) receptor subtypes.